Lavaca Capital LLC Buys 295 Shares of Bristol-Myers Squibb (NYSE:BMY)

Lavaca Capital LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,395 shares of the biopharmaceutical company’s stock after buying an additional 295 shares during the quarter. Lavaca Capital LLC’s holdings in Bristol-Myers Squibb were worth $238,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BMY. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $27,000. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. Accordant Advisory Group Inc acquired a new position in Bristol-Myers Squibb during the first quarter worth approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY traded down $1.48 during mid-day trading on Monday, reaching $48.97. The company had a trading volume of 22,276,796 shares, compared to its average volume of 15,962,543. The firm has a market cap of $99.27 billion, a price-to-earnings ratio of -15.80, a PEG ratio of 17.25 and a beta of 0.44. The business’s 50-day simple moving average is $41.87 and its 200 day simple moving average is $46.75. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 11.52%. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same period last year, the firm earned $1.75 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, research analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.90%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Analyst Ratings Changes

A number of research analysts recently weighed in on BMY shares. Barclays lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 target price on the stock. in a report on Monday. Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $55.79.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.